GDTC CytoMed Therapeutics Ltd
Price Chart
Executive Summary
CytoMed Therapeutics reported full-year 2025 financial results with revenue growth to $780,857 but a wider net loss of $3.11 million, up from $1.96 million in 2024, driven by increased R&D and employee expenses. The company highlighted clinical progress in its CAR-T and unmodified gamma delta T cell programs, including a new MOU with Universiti Malaya for a Phase I trial in Malaysia and co-publication with MD Anderson on AML potential. Cash reserves declined to $1.63 million from $3.87 million, raising near-term liquidity concerns despite claims of sufficient funding.
Actionable Insight
While the company is advancing its clinical pipeline with multiple trials and strategic collaborations, the significant cash burn and declining reserves pose near-term execution risks. Traders should monitor upcoming milestones, including IND submission in Malaysia by June 2026 and completion of the Singapore CAR-T trial, as well as any potential financing activities given the reduced cash balance.
Key Facts
- Total revenue increased to $780,857 in 2025 from $663,786 in 2024
- Audited net loss widened to $3.11 million in 2025 from $1.96 million in 2024
- Cash and bank balances declined to $1.63 million as of December 31, 2025, from $3.87 million a year earlier
- Research expenses rose to $1.72 million in 2025 from $1.48 million in 2024
- Employee benefits expenses increased to $723,667 in 2025 from $481,629 in 2024, including $240,491 in share-based compensation
- First-in-human ANGELICA CAR-T Phase I trial in Singapore is progressing to dose level 3, with completion targeted in 2026
- Memorandum of Understanding signed with Universiti Malaya to launch a Phase I trial for unmodified gamma delta T cells in Malaysia
- Co-authored preclinical study with MD Anderson suggests potential of CTM-GDT therapy for acute myeloid leukemia (AML)
- Acquired assets of a Malaysian cord blood bank, including a private blood bank license, through subsidiary IPSC Depository Sdn. Bhd.
- Made an equity investment in a Malaysian general medical clinic services provider
Financial Impact
Revenue increased 17.6% YoY to $780,857, but net loss expanded by 58.7% to $3.11 million. Cash burn was $2.24 million in 2025, with cash reserves now at $1.63 million.
Risk Factors
- High cash burn rate and declining cash reserves may necessitate near-term dilutive financing
- Clinical trial delays or adverse safety signals could impact development timelines
- Reliance on co-funding and partnerships introduces execution and dependency risk
- Small market cap ($12M) increases volatility and susceptibility to sentiment shifts
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-013882 |
| Document: 0001493152-26-013882-index-headers.html | 0001493152-26-013882 |
| Document: 0001493152-26-013882-index.html | 0001493152-26-013882 |
| Document: 0001493152-26-013882.txt | 0001493152-26-013882 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 15, 2026
29d ago
|
6-K
| $1.16 $1.13 | ▼ −2.59% | ▼ −3.55% | $1.14 (−1.72%) |
|
May 11, 2026
4w ago
|
6-K
| $0.8090 $1.21 | ▲ +49.57% | ▲ +49.65% | $1.14 (+40.91%) |
|
Mar 31, 2026
10w ago
|
6-K
| $1.00 $1.00 | · 0.00% | ▼ −3.94% | $1.14 (+14.00%) |
|
Mar 31, 2026
10w ago
|
20-F
| $1.00 $1.00 | · 0.00% | ▼ −3.94% | $1.14 (+14.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access